These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 28526488)

  • 1. Targeting the gut-liver axis in liver disease.
    Wiest R; Albillos A; Trauner M; Bajaj JS; Jalan R
    J Hepatol; 2017 Nov; 67(5):1084-1103. PubMed ID: 28526488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal microbiota in liver disease.
    Haque TR; Barritt AS
    Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):133-42. PubMed ID: 27048904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation].
    Aitbaev KA; Murkamilov IT; Fomin VV
    Ter Arkh; 2017; 89(8):120-128. PubMed ID: 28914862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction.
    Lechner S; Yee M; Limketkai BN; Pham EA
    Dig Dis Sci; 2020 Mar; 65(3):897-905. PubMed ID: 32020359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of gut microbiota in chronic liver diseases, and treatment possibilities].
    Hagymási K; Bacsárdi A; Egresi A; Berta E; Tulassay Z; Lengyel G
    Orv Hetil; 2018 Sep; 159(36):1465-1474. PubMed ID: 30175608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota changes and chronic hepatitis C virus infection.
    Preveden T; Scarpellini E; Milić N; Luzza F; Abenavoli L
    Expert Rev Gastroenterol Hepatol; 2017 Sep; 11(9):813-819. PubMed ID: 28621554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature.
    Giuffrè M; Campigotto M; Campisciano G; Comar M; Crocè LS
    Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G889-G906. PubMed ID: 32146836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alcohol, liver disease and the gut microbiota.
    Bajaj JS
    Nat Rev Gastroenterol Hepatol; 2019 Apr; 16(4):235-246. PubMed ID: 30643227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human microbiome restoration and safety.
    Daliri EB; Tango CN; Lee BH; Oh DH
    Int J Med Microbiol; 2018 Jul; 308(5):487-497. PubMed ID: 29773467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.
    Milosevic I; Vujovic A; Barac A; Djelic M; Korac M; Radovanovic Spurnic A; Gmizic I; Stevanovic O; Djordjevic V; Lekic N; Russo E; Amedei A
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Dysbiosis for the Treatment of Liver Disease.
    Anand G; Zarrinpar A; Loomba R
    Semin Liver Dis; 2016 Feb; 36(1):37-47. PubMed ID: 26870931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation.
    Jayasinghe TN; Chiavaroli V; Holland DJ; Cutfield WS; O'Sullivan JM
    Front Cell Infect Microbiol; 2016; 6():15. PubMed ID: 26925392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The gut microbiota-bile acid axis in cholestatic liver disease.
    Sun D; Xie C; Zhao Y; Liao J; Li S; Zhang Y; Wang D; Hua K; Gu Y; Du J; Huang G; Huang J
    Mol Med; 2024 Jul; 30(1):104. PubMed ID: 39030473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus on the gut-brain axis: Multiple sclerosis, the intestinal barrier and the microbiome.
    Camara-Lemarroy CR; Metz LM; Yong VW
    World J Gastroenterol; 2018 Oct; 24(37):4217-4223. PubMed ID: 30310254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiome alterations observed in liver diseases present opportunities for potential fecal transplantation.
    Heath RD; Mir F; Ibdah JA; Tahan V
    Turk J Gastroenterol; 2016 Nov; 27(6):495-498. PubMed ID: 27852539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism of gut-microbiota-liver axis in the pathogenesis of intestinal failure-associated liver disease].
    Fan SX; Wang J; Li Q; Li YS; Guan WX; Li JS
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Jan; 24(1):94-100. PubMed ID: 33461259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The gut microbiota, a new cardiovascular risk factor?].
    Chong-Nguyen C; Duboc H; Sokol H
    Presse Med; 2017; 46(7-8 Pt 1):708-713. PubMed ID: 28756077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promises of microbiome-based therapies.
    Bajaj JS; Ng SC; Schnabl B
    J Hepatol; 2022 Jun; 76(6):1379-1391. PubMed ID: 35589257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis.
    Bajaj JS; Khoruts A
    J Hepatol; 2020 May; 72(5):1003-1027. PubMed ID: 32004593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.